Cargando…

Boosting capacity of a fourth dose BNT162b2 in cancer patients

Detalles Bibliográficos
Autores principales:	Debie, Yana, van Dam, Peter A, Goossens, Maria E, Peeters, Marc, Vandamme, Timon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686056/ https://www.ncbi.nlm.nih.gov/pubmed/36521333 http://dx.doi.org/10.1016/j.ejca.2022.11.016

Ejemplares similares

Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer
por: Debie, Yana, et al.
Publicado: (2022)

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
por: Di Noia, Vincenzo, et al.
Publicado: (2022)

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
por: Lasagna, A., et al.
Publicado: (2022)

1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
por: Debie, Y., et al.
Publicado: (2022)

Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients
por: van Dam, P.A., et al.
Publicado: (2022)

Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors
por: Konnova, Angelina, et al.
Publicado: (2022)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Acute myocarditis after a third dose of the BNT162b2 COVID-19 vaccine
por: Fosch, Xavier, et al.
Publicado: (2022)

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer
por: Di Noia, V., et al.
Publicado: (2022)

The SARS-CoV-2–neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine
por: Pedersen, Rune M., et al.
Publicado: (2021)

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Magen, Ori, et al.
Publicado: (2022)

Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients
por: Attias, Philippe, et al.
Publicado: (2021)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease
por: Stervbo, Ulrik, et al.
Publicado: (2021)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Restoration of Neutralization Activity Against Omicron BA.2 and BA.5 in Older Adults and Individuals With Risk Factors Following the Fourth Dose of Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Vaccine
por: Amano, Masayuki, et al.
Publicado: (2022)

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis
por: Ducloux, Didier, et al.
Publicado: (2021)

Impact of first dose of BNT162b2 vaccine on COVID-19 infection among healthcare workers in an Irish hospital
por: Walsh, Jennifer, et al.
Publicado: (2021)

Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan
por: Nishikimi, Akihiko, et al.
Publicado: (2023)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
por: Güney, Tekin, et al.
Publicado: (2022)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
por: Lam, Chi-Yan, et al.
Publicado: (2023)

Recurrent Aseptic Meningoencephalitis Following BNT162b2 Vaccination for COVID-19
por: Kang, Kyusik, et al.
Publicado: (2022)

Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine
por: Ferré, Valentine Marie, et al.
Publicado: (2022)

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
por: Ruhe, Johannes, et al.
Publicado: (2021)

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
por: Peeters, M., et al.
Publicado: (2021)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
por: Hamada, Yohhei
Publicado: (2021)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine
por: Juddoo, Vanessa, et al.
Publicado: (2022)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
por: Nishizawa, Toshinori, et al.
Publicado: (2022)

Insulin allergy manifesting soon after COVID‐19 vaccination (BNT162b2)
por: Komamura, Hiroshi, et al.
Publicado: (2022)

Comments on “Recurrent Aseptic Meningoencephalitis Following BNT162b2 Vaccination for COVID-19”
por: Finsterer, Josef
Publicado: (2023)

Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population
por: Malissen, Nausicaa, et al.
Publicado: (2021)

T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients
por: Heitz, Jade, et al.
Publicado: (2022)

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2
por: Hayashi, Jackelinne Y., et al.
Publicado: (2022)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_is4p10gsdm527d0cd3h0vm0pb0